• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

盐水抑制试验诱发的低钙血症及其对临床解释的影响。

Saline suppression testing-induced hypocalcemia and implications for clinical interpretations.

机构信息

Center for Adrenal Disorders, Boston, MA 02115, United States.

Division of Endocrinology, Diabetes, and Hypertension, Boston, MA 02115, United States.

出版信息

Eur J Endocrinol. 2024 Aug 5;191(2):241-250. doi: 10.1093/ejendo/lvae099.

DOI:10.1093/ejendo/lvae099
PMID:39073780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11322817/
Abstract

BACKGROUND

Extracellular calcium critically regulates physiologic aldosterone production. Moreover, abnormal calcium flux and signaling are involved in the pathogenesis of the majority of primary aldosteronism cases.

METHODS

We investigated the influence of the saline suppression test (SST) on calcium homeostasis in prospectively recruited participants (n = 86).

RESULTS

During SST, 100% of participants had decreases in serum calcium, with 48% developing frank hypocalcemia. Serum calcium declined from 2.30 ± 0.08 mmol/L to 2.13 ± 0.08 mmol/L (P < .001) with parallel increases in parathyroid hormone from 6.06 ± 2.39 pmol/L to 8.13 ± 2.42 pmol/L (P < .001). In contrast, serum potassium and bicarbonate did not change, whereas eGFR increased and serum glucose decreased (P < .001). Lower body surface area (translating to greater effective circulating volume expansion during SST) was associated with greater reductions in (β = .33, P = .001), and absolutely lower, serum calcium levels (β = .25, P = .001). When evaluating clinically-relevant diagnostic thresholds, participants with post-SST aldosterone levels <138 pmol/L had lower post-SST calcium and 25-hydroxyvitamin D levels (P < .05), and higher post-SST parathyroid hormone levels (P < .05) compared with those with post-SST aldosterone levels >277 pmol/L.

CONCLUSION

SST uniformly decreases serum calcium, which is likely to be due to the combination of variable dilution, increased renal clearance, and vitamin D status. These acute reductions in bioavailable calcium are associated with lower post-SST aldosterone. Given the critical role of extracellular calcium in regulating aldosterone production, these findings warrant renewed inquiry into the validity of SST interpretations for excluding primary aldosteronism.

摘要

背景

细胞外钙对生理醛固酮的产生具有关键调节作用。此外,异常的钙流和信号转导参与了大多数原发性醛固酮增多症病例的发病机制。

方法

我们前瞻性地招募了参与者(n=86),研究了盐水抑制试验(SST)对钙稳态的影响。

结果

在 SST 期间,100%的参与者血清钙下降,其中 48%出现明显低钙血症。血清钙从 2.30±0.08mmol/L 降至 2.13±0.08mmol/L(P<0.001),同时甲状旁腺激素从 6.06±2.39pmol/L 增至 8.13±2.42pmol/L(P<0.001)。相比之下,血清钾和碳酸氢盐没有变化,而 eGFR 增加,血糖降低(P<0.001)。较低的体表面积(在 SST 期间转化为更大的有效循环容量扩张)与血清钙水平的更大降低相关(β=0.33,P=0.001),并且血清钙水平绝对较低(β=0.25,P=0.001)。当评估临床相关的诊断阈值时,SST 后醛固酮水平<138pmol/L 的患者 SST 后钙和 25-羟维生素 D 水平较低(P<0.05),SST 后甲状旁腺激素水平较高(P<0.05),而 SST 后醛固酮水平>277pmol/L 的患者则较低。

结论

SST 一致降低血清钙,这可能是由于稀释、肾清除率增加和维生素 D 状态的变化。这些生物利用钙的急性减少与 SST 后醛固酮降低有关。鉴于细胞外钙在调节醛固酮产生中的关键作用,这些发现值得重新探讨 SST 解释排除原发性醛固酮增多症的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2934/11322817/ae5d14acd547/lvae099_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2934/11322817/ae5d14acd547/lvae099_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2934/11322817/ae5d14acd547/lvae099_ga.jpg

相似文献

1
Saline suppression testing-induced hypocalcemia and implications for clinical interpretations.盐水抑制试验诱发的低钙血症及其对临床解释的影响。
Eur J Endocrinol. 2024 Aug 5;191(2):241-250. doi: 10.1093/ejendo/lvae099.
2
Effectiveness and safety of vitamin D in relation to bone health.维生素D对骨骼健康的有效性与安全性。
Evid Rep Technol Assess (Full Rep). 2007 Aug(158):1-235.
3
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.帕洛昔肽治疗改善慢性甲状旁腺功能减退症成人的肾功能:来自 3 期 PaTHway 试验的 1 年结果。
Adv Ther. 2024 Jun;41(6):2500-2518. doi: 10.1007/s12325-024-02843-8. Epub 2024 Apr 30.
4
The diagnostic utility of the captopril challenge test for primary aldosteronism in a Bangladeshi population: a prospective study.卡托普利激发试验对孟加拉人群原发性醛固酮增多症的诊断效用:一项前瞻性研究。
Pathology. 2025 Jun 6. doi: 10.1016/j.pathol.2025.04.003.
5
The saline infusion test with mass spectrometric measurements of aldosterone to confirm primary aldosteronism.通过质谱法测量醛固酮进行盐水输注试验以确诊原发性醛固酮增多症。
J Hypertens. 2025 Jul 16. doi: 10.1097/HJH.0000000000004098.
6
Confirmatory Testing for Primary Aldosteronism : A Study of Diagnostic Test Accuracy.原发性醛固酮增多症的验证性检测:诊断试验准确性研究
Ann Intern Med. 2025 Jul;178(7):948-956. doi: 10.7326/ANNALS-24-03153. Epub 2025 May 6.
7
Eiken syndrome with parathyroid hormone resistance due to a novel parathyroid hormone receptor type 1 mutation: clinical features and functional analysis.由于甲状旁腺激素受体 1 型突变导致的 Eiken 综合征伴甲状旁腺激素抵抗:临床特征和功能分析。
J Bone Miner Res. 2024 Oct 29;39(11):1596-1605. doi: 10.1093/jbmr/zjae148.
8
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
9
Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism.系统评价:原发性醛固酮增多症中鉴别单侧与双侧肾上腺异常的诊断方法
Ann Intern Med. 2009 Sep 1;151(5):329-37. doi: 10.7326/0003-4819-151-5-200909010-00007.
10
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.单侧原发性醛固酮增多症肾上腺切除术的结局:国际共识的结局指标和国际队列缓解率分析。
Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3. Epub 2017 May 30.

引用本文的文献

1
Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism.原发性醛固酮增多症中醛固酮抑制试验的不一致性和不足之处。
Eur J Endocrinol. 2025 Aug 29;193(3):348-358. doi: 10.1093/ejendo/lvaf170.

本文引用的文献

1
The Spectrum of Dysregulated Aldosterone Production: An International Human Physiology Study.醛固酮分泌失调谱:一项国际人体生理学研究。
J Clin Endocrinol Metab. 2024 Aug 13;109(9):2220-2232. doi: 10.1210/clinem/dgae145.
2
Long-Term Follow-Up of Patients With Elevated Aldosterone-to-Renin Ratio but Negative Confirmatory Test: The Progression of Primary Aldosteronism Phenotypes.醛固酮/肾素比值升高但确诊试验阴性患者的长期随访:原醛症表型的进展。
Hypertension. 2024 Feb;81(2):340-347. doi: 10.1161/HYPERTENSIONAHA.123.21983. Epub 2023 Dec 12.
3
Primary aldosteronism: molecular medicine meets public health.
原发性醛固酮增多症:分子医学与公共卫生的交汇。
Nat Rev Nephrol. 2023 Dec;19(12):788-806. doi: 10.1038/s41581-023-00753-6. Epub 2023 Aug 23.
4
Somatic mutations of CADM1 in aldosterone-producing adenomas and gap junction-dependent regulation of aldosterone production.醛固酮瘤中 CADM1 的体细胞突变和缝隙连接依赖性的醛固酮产生调节。
Nat Genet. 2023 Jun;55(6):1009-1021. doi: 10.1038/s41588-023-01403-0. Epub 2023 Jun 8.
5
Saline suppression to distinguish the primary aldosteronism subtype: a diagnostic study.盐水抑制试验以区分原发性醛固酮增多症亚型:一项诊断性研究。
Eur J Endocrinol. 2023 Jan 10;188(1). doi: 10.1093/ejendo/lvac003.
6
New advances in endocrine hypertension: from genes to biomarkers.内分泌性高血压的新进展:从基因到生物标志物
Kidney Int. 2023 Mar;103(3):485-500. doi: 10.1016/j.kint.2022.12.021. Epub 2023 Jan 13.
7
Exclusion Tests in Unilateral Primary Aldosteronism (ExcluPA) Study.单侧原发性醛固酮增多症排除试验(ExcluPA)研究
J Clin Endocrinol Metab. 2023 Jan 17;108(2):496-506. doi: 10.1210/clinem/dgac654.
8
Primary aldosteronism: Pathophysiological mechanisms of cell death and proliferation.原发性醛固酮增多症:细胞死亡和增殖的病理生理机制。
Front Endocrinol (Lausanne). 2022 Aug 8;13:934326. doi: 10.3389/fendo.2022.934326. eCollection 2022.
9
Primary Aldosteronism: State-of-the-Art Review.原发性醛固酮增多症:最新研究综述。
Am J Hypertens. 2022 Dec 8;35(12):967-988. doi: 10.1093/ajh/hpac079.
10
Performance of Confirmatory Tests for Diagnosing Primary Aldosteronism: a Systematic Review and Meta-Analysis.用于诊断原发性醛固酮增多症的确诊性试验的性能:系统评价和荟萃分析。
Hypertension. 2022 Aug;79(8):1835-1844. doi: 10.1161/HYPERTENSIONAHA.122.19377. Epub 2022 Jun 2.